ClinicalTrials.Veeva

Menu

Transcriptomic Evaluation of Endometrial Receptivity

R

Reproductive Medicine Associates of New Jersey

Status

Completed

Conditions

Infertility, Female

Treatments

Other: Endometrial biopsy

Study type

Observational

Funder types

Other

Identifiers

NCT04141085
RMA-2019-01

Details and patient eligibility

About

The purpose of this study is to comprehensively evaluate the transcriptomic signal of the endometrium before, during, and after the window of receptivity.

Full description

Phase 1 will aim to define a normal endometrial transcriptomic signature in healthy controls without infertility. Phase 2 will elucidate endometrial transcriptomic expression in patients with diagnoses of infertility unrelated to endometrial factor. Findings from this phase will be compared to the results of phase 1.

Enrollment

63 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Phase 1:

Major Inclusion: The following are major inclusion criteria:

  1. Regular menstrual cycles
  2. Age 18-50
  3. Normal baseline ultrasound
  4. No intrauterine procedures in prior 90 days

Exclusions: The following are exclusion criteria:

  1. Any contraindications to undergoing estrogen stimulation of the endometrium

    1. Current smoking status
    2. Multiple risk factors for arterial cardiovascular disease (smoking, diabetes, and hypertension)
    3. Hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg)
    4. Venous thromboembolism (current or history of)
    5. Known thrombogenic mutations
    6. Known ischemic heart disease
    7. History of stroke
    8. Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)
    9. Systemic lupus erythematosus (positive or unknown antiphospholipid antibodies)
    10. Migraine with aura at any age
    11. Breast cancer
    12. Cirrhosis
    13. Hepatocellular adenoma or malignant hepatoma
  2. History of infertility diagnosis

  3. History of undiagnosed abnormal uterine bleeding.

  4. Allergic reaction to any medication used for the preparatory cycle

  5. Known pregnancy or delivery within the past 6 months

  6. Breastfeeding

  7. Obesity >35 kg/m2

Phase 2

Major Inclusion: The following are major inclusion criteria:

  1. Age 18-50
  2. Diagnosis of infertility with low endometrial risk
  3. No intrauterine procedures in prior 90 days

Exclusions: In addition to the exclusion criteria for phase 1, patients deemed to have an elevated endometrial risk will also be excluded. This would include the following:

  1. Recurrent implantation failure
  2. Failed transfer with a euploid blastocyst
  3. History of Asherman's or abnormal endometrial function
  4. History of endometriosis

Trial design

63 participants in 2 patient groups

Healthy volunteers without infertility
Description:
Healthy volunteers without a history of infertility who have regular menstrual cycles and whom have not had any intrauterine procedures performed in the last 90 days prior to participation in the study
Treatment:
Other: Endometrial biopsy
Infertile Patients
Description:
Infertile patients with a history of infertility but without concern for endometrial dysfunction as the cause of their infertility.
Treatment:
Other: Endometrial biopsy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems